NICAM: Nilotinib treatment for c-KIT mutated advanced AMM

Phase II single arm study evaluating the activity of nilotinib in rare c-KIT mutated acral and mucosal melanoma (AMM). Entry into the trial is a 2 step process. Patients presenting with AMM are first registered (Step 1) for screening including confirmation of c-KIT mutation status. Eligible patients who proceed to study entry (step 2) commence treatment with nilotinib 400 mgs twice daily for as long as they continue to benefit from treatment.

Existing samples:

  • Malignant melanoma of eye (disorder)

Networks

  • ICR Clinical Trials & Statistics Unit (ICR-CTSU)

Contact Information

Email:
nicam-icrctsu@icr.ac.uk
Address:

ICR-CTSU
The Institute of Cancer Research
15 Cotswold Road
Sutton
Surrey
SM2 5NG
UK

Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A